💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Column-Medicare open enrollment: A chance to tune up your coverage

Published 10/14/2022, 03:58 PM
Updated 10/14/2022, 05:25 PM
© Reuters

By Mark Miller

(Reuters) - Fall is the time to give your Medicare coverage a checkup. This is a chore far too many seniors shy away from, but it can be a money-saving move that improves your access to healthcare.

Open enrollment begins on Oct. 15 and runs through Dec. 7, but seven out of ten Medicare beneficiaries probably will not compare their coverage options, if the latest data from the Kaiser Family Foundation is any indication. 

If you are enrolled in traditional Medicare with a Medigap supplemental plan, there is no need to re-evaluate or make changes. But anyone enrolled in a Medicare Advantage or Part D prescription drug plan should do a checkup annually. The terms of your Part D coverage can change from year to year in ways that affect not only your costs, but access to medications. The same is true for Advantage plans that wrap in drug coverage - and the healthcare providers included in these managed care networks also can change.

This fall, there is some good news for seniors enrolled in Medicare for 2023, as some costs are falling. But the plan- shopping process can be complex - and there are pitfalls to avoid.

One pleasant surprise for next year is a falling Part B premium. The standard monthly Part B premium will drop next year by $5.20, to $164.90, and the annual Part B deductible will also decline, by $7, to $226. The very unusual decline is the result of the recent fracas surrounding Aduhelm, the controversial, very expensive drug for treating Alzheimer’s Disease, is administered in outpatient settings, so it is covered under Part B. 

The Food and Drug Administration approved Aduhelm in 2021, and - assuming that the drug would be covered - Medicare increased the 2022 Part B premium by a whopping 14.5% to $170.10 per month. But Medicare ultimately decided to limit coverage to certain clinical trials - which meant beneficiaries have been overcharged this year. 

The premium drop next year amounts to a refund of that overcharge.

Seniors can count on adding that $5.20 monthly refund to the hefty 8.7% Social Security cost-of-living adjustment (COLA) for 2023 announced on Thursday. Part B premium hikes often consume a good part of the Social Security COLA - but not in 2023. 

The landmark Inflation Reduction Act phases in changes to Medicare over several years that should help moderate costs. In 2023, vaccines covered under Part D come with no copays or deductibles, which should help with expensive jabs such as the shingles vaccine. 

The IRA also caps the soaring cost of insulin, with a maximum monthly copay for Medicare enrollees of $35 - a godsend for diabetics. However, this improvement comes with one caution for beneficiaries shopping for Part D plans using the Medicare Plan Finder, according to Frederic Riccardi, president of the Medicare Rights Center.

Since the IRA was passed so recently, the insulin copay cap will not be reflected in online descriptions of plan costs. Riccardi recommends running searches for plans by making sure your insulin prescription is included in a plan’s list of covered drugs (the formulary), and then omitting insulin from your list of drugs. “So long as a plan does include insulin in its list of covered drugs, you can estimate your costs by adding back in the $35 copay,” he said.

CHANGING YOUR BASIC COVERAGE

Open enrollment offers an annual opportunity to switch between traditional Medicare and Advantage. 

Switching out of the traditional program could save you money on upfront premium costs - but the move does come with tradeoffs. These plans incentivize you to use in-network health providers, which may limit your choices.

You also will be jumping through the hoops of paperwork and processes that insurance companies use to manage your care - and sometimes, deny it. A report issued earlier this year by the Office of the Inspector General at the U.S. Department of Health and Human Services noted that Medicare audits of Advantage plans “have highlighted widespread and persistent problems related to inappropriate denials of services and payment.” The report found that denials of requests "that meet Medicare coverage rules may prevent or delay beneficiaries from receiving medically necessary care and can burden providers."

You also can leave Advantage for traditional Medicare during the enrollment period. But do this with caution. Seniors who use traditional Medicare should have supplemental coverage, often through a commercial Medigap plan. You are guaranteed access to these policies at the point of initial enrollment in Part B - but after this period, Medigap plans in most states can reject applications or charge higher premiums due to pre-existing conditions, with the exception of four states that protect Medigap applicants beyond that time (New York, Connecticut, Maine and Massachusetts all have some form of guaranteed issue rules for later Medigap enrollment.)

SHOPPING RESOURCES

Start your shopping process by reviewing the Annual Notice of Change letter that comes each autumn from your Medicare prescription drug or Advantage plan provider. The annual notice details any changes in rules for cost-sharing, coverage of specific medications in your current plan, and even whether a specific drug will be covered.

The State Health Insurance Assistance Program network provides free one-on-one assistance in every state. These are federally funded programs staffed by trained volunteers; use this link to find yours.

The Medicare Rights Center offers a free consumer helpline: (800-333-4114.)

© Reuters. FILE PHOTO: George Washington is seen with printed medical mask on the one Dollar banknotes in this illustration taken, March 31, 2020. REUTERS/Dado Ruvic/Illustration

When it comes time to enroll, call Medicare to sign up (800-633-4227) and to ensure that your enrollment has been processed.

The opinions expressed here are those of the author, a columnist for Reuters.

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.